Dr. Alison E. Willing

• 
  www.msrc.co.uk/index.cfm?fuseaction=show&pageid=2394&CF - [Cached Version]
  Published on: 3/1/2008    Last Visited: 6/20/2008  

  "Brain cell neurogenesis decreases dramatically with increasing age, mostly because of a growing impoverishment in the brain's microenvironment," said co-author Alison Willing, PhD, of the USF Center of Excellence for Aging and Brain Repair.

• 
  pasco.tbo.com/pasco/MGBWIVB0A6F.html - [Cached Version]
  Published on: 9/7/2007    Last Visited: 9/7/2007  

  Alison Willing, associate professor of neurosurgery at the USF Health Center for Aging, has helped with Hammer's studies during the past two years.A researcher in neuroscience for about 20 years, she said his drive led her to lend her expertise to his project, and it was the second major study she's worked on with him.
  
  Joshua said he began studying the CD4 proteins after Willing told him to research T-cells, and he came across them.He said the cells function as the main protein involved in the virus was interesting and his studies grew from there.
  
  "The thing that makes him so enjoyable to work with is his enthusiasm about everything," she said.

• 
  www.medcentral.org/body.cfm?id=303&action=detail&ref=21 - [Cached Version]
  Published on: 3/1/2008    Last Visited: 3/18/2008  

  "Brain cell neurogenesis decreases dramatically with increasing age, mostly because of a growing impoverishment in the brain's microenvironment," study co-author Alison Willing, of the USF Center of Excellence for Aging and Brain Repair, said in a prepared statement.

• 
  www.hope4stroke.com/2380/7193.html?*session*id*key*=*se - [Cached Version]
  Last Visited: 1/31/2008  

  An article in the same issue of Stroke by the USF researchers led by Dr. Alison Willing, neuroscientist, shows that 10 times the number of stem cells or more would be needed to produce similar results if cells were given intravenously without any help crossing the blood-brain barrier.
  ...
  Drs. Borlongan and Willing are consultants and Dr. Sanberg is cofounder of Saneron CCEL Therapeutics, Inc.

• 
  www.cordblood.com/cord_blood_news/stem_cell_news/a_cord - [Cached Version]
  Published on: 12/3/2006    Last Visited: 3/11/2007  

  Other authors of the study were Hamdi Abu-Ali; MD; John Balis, MD; Michael B. Morgan, MD; and Alison E. Willing, PhD.

• 
  ::Coalition For Brain Injury Research:: - [Cached Version]
  Published on: 2/18/2001    Last Visited: 1/28/2005  

  Principal researchers on these trials included Dr. Sanberg, who is director of the USF Center for Aging and Brain Repair and director of Neurosurgical Research; Dr. Sanchez Ramos, Professor of neurology and holder of the Ellis Chair in Parkinson's Disease Research; Alison Willing, PhD, member of the USF Center for Aging and Brain Repair; and Michael Chopp, PhD, Professor and Vice Chairman of Neurology, Henry Ford Hospital.

• 
  ADVANCE for Speech-Language Pathologists and... - [Cached Version]
  Published on: 11/10/2004    Last Visited: 12/19/2005  

  "We were very surprised," said principal investigator Alison Willing, PhD, a neuroscientist at the USF Center of Excellence for Aging and Brain Repair."In some animals, the stroke initially damaged half the brain, but after treatment with the cord blood cells they were functioning normally.
  
  "These findings show we are able to rescue neurons at a time when most research suggests they are already dead."
  
  Dr. Willing presented the preliminary findings last month at the Society for Neuroscience annual meeting in Washington, DC.
  
  The only drug currently approved for ischemic stroke treatment is tPA (tissue plasminogen activator), which breaks up blood clots - the cause of most strokes.However, tPA must be given within three hours following a stroke to be effective and few patients arrive at the hospital quickly enough to receive it.Even when a patient meets the recommended three-hour treatment criteria, smaller hospitals often lack ready access to a CT scan, a test needed to rule out a hemorrhagic stroke caused by a burst blood vessel.The drug can worsen this less common type of stroke.
  
  "New and more flexible treatments are needed to help more patients," Dr. Willing said.
  ...
  "This delayed death would permit more time to deliver neuron-sparing treatments than originally thought," Dr. Willing said.
  
  The USF researchers continue to investigate the ways cord blood cells aid stroke recovery in animals, and will begin a study to determine the timing of brain inflammatory responses in acute stroke patients.
  
  Researchers working with Dr. Willing were Jennifer Newcomb, Ted Ajmo, Lisa Collier, Cyndy Davis Sanberg, PhD; Keith Pennypacker, PhD; and Paul R. Sanberg, DSc, PhD.
  ...
  Dr. Sanberg is a cofounder of Saneron CCEL, and Dr. Willing is a consultant.

• 
  Apologetics Press - Presidential Elections, Superman,... - [Cached Version]
  Published on: 4/1/2003    Last Visited: 7/24/2006  

  Lead researcher: Alison Willing, University of South Florida
  
  In a study led by Dr. Alison Willing, stem-like cells extracted from human bone marrow were injected into rats that had experienced severe strokes.

• 
  Are Currently Available Drugs Effective in ALS? - [Cached Version]
  Published on: 2/1/2002    Last Visited: 6/30/2004  

  Alison Willing, PhD, of the Departments of Neurosurgery and Anatomy, University of South Florida, Tampa, did intraspinal implants of hNT neurons (derived from the human teratocarcinoma cell line NTera2/D1) at L4 and L5 in SOD1 mice.A delay in progression of motor symptoms of three to four weeks was found, although life span was unaffected.Immunohistochemical analysis of the implanted spinal cords also demonstrated survival of the neurons, she noted.
  
  In earlier research, she had also found that such implants into SOD1 mice before symptoms develop delayed their onset."While preliminary," she said, "these studies suggest that such intraspinal implants might well help humans with ALS."

Page:  1 2 3